CRLF2 rearrangement
|
ALL
|
CRLF2 rearrangement
|
ALL
|
T-lymphocyte cell therapy + ruxolitinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
T-lymphocyte cell therapy + ruxolitinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
CRLF2 rearrangement
|
ALL
|
CRLF2 rearrangement
|
ALL
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CRLF2 rearrangement
|
ALL
|
CRLF2 rearrangement
|
ALL
|
ruxolitinib Sensitive: C2 – Inclusion Criteria
|
ruxolitinib Sensitive: C2 – Inclusion Criteria
|
CRLF2 rearrangement
|
AML
|
CRLF2 rearrangement
|
AML
|
ruxolitinib Sensitive: D – Preclinical
|
ruxolitinib Sensitive: D – Preclinical
|